Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jornay PM is a prescription central nervous system stimulant containing methylphenidate hydrochloride in delayed-release and extended-release capsules. It is indicated for attention deficit hyperactivity disorder in patients age 6 and older. Current capsule strengths are 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg.
read more about jornay pm ...Methylphenidate blocks reuptake of norepinephrine and dopamine into presynaptic neurons and increases release of these monoamines into the space outside neurons. The exact mechanism responsible for its therapeutic effects in attention deficit hyperactivity disorder is not established.
Jornay PM is used for attention deficit hyperactivity disorder in patients age 6 and older. Use is not recommended in children younger than 6 due to higher exposure and a greater incidence of adverse reactions at the same dose.
The recommended starting dose is 20 mg once daily in the evening. Treatment begins with dosing around 8 p.m., and the administration time can be adjusted between half past 6 p.m. and half past 9 p.m. The dose can increase by 20 mg at weekly intervals up to 100 mg daily. Jornay PM is not taken in the morning.
Jornay PM carries a boxed warning for abuse, misuse, and addiction. Misuse can result in overdose and death. Other serious concerns include sudden death in patients with serious cardiac disease, increased blood pressure and heart rate, psychiatric reactions, priapism, peripheral vasculopathy, slowed growth in children, glaucoma, and worsening tics or Tourette syndrome.
Jornay PM treats attention deficit hyperactivity disorder in patients age 6 and older.
Jornay PM is taken once daily in the evening rather than in the morning.
The maximum recommended dose is 100 mg once daily.
Yes. The boxed warning concerns abuse, misuse, and addiction.
A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children With Attention-Deficit/Hyperactivity Disorder. https://pubmed.ncbi.nlm.nih.gov/31464511/. Date Accessed October 6, 2026.
Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children With Attention-Deficit/Hyperactivity Disorder. https://pubmed.ncbi.nlm.nih.gov/29172680/. Date Accessed October 6, 2026.
JORNAY PM (Methylphenidate Hydrochloride) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d95dede0-b1ff-4489-8f91-3bbe122852bf. Date Accessed October 6, 2026.
Jornay PM: Evening-Dosed Methylphenidate for ADHD. https://pubmed.ncbi.nlm.nih.gov/31386648/. Date Accessed October 6, 2026.
Methylphenidate: MedlinePlus Drug Information. https://www.medlineplus.gov/druginfo/meds/a682188.html. Date Accessed October 6, 2026.